Enanta Pharmaceuticals Logo

 
 

An estimated 150 million people worldwide are chronically infected with HCV

From Chemistry to Cures

More than 350,000 people die every year from HCV-related liver diseases

From Chemistry to Cures

The CDC estimated approximately 3.2 million people
in the U.S. are chronically infected with HCV

From Chemistry to Cures

ABOUT ENANTA

We are a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. We are discovering and developing novel inhibitors designed for use against the hepatitis C virus, or HCV. Learn more about us.

Our Vision

Our primary objective is to become a leader in the infectious disease field, with a focus on HCV and multi-drug-resistant bacterial infections. Learn more.

Our Research

We are pursuing four fundamental, validated targets within the HCV field that represent a broad approach to the disease and specifically address the urgent unmet medical needs for the treatment of HCV. Learn more.